{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:47Z","timestamp":1753891967433,"version":"3.41.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81800194"],"award-info":[{"award-number":["No. 81800194"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81770210"],"award-info":[{"award-number":["No.81770210"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81473486"],"award-info":[{"award-number":["No.81473486"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82070203, No.81270598"],"award-info":[{"award-number":["No. 82070203, No.81270598"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Although pegylated liposomal doxorubicin (PLD) has been approved in combination with bortezomib for relapsed\/refractory multiple myeloma (MM), the antitumor efficacy and tolerability of PLD in different regimens for patients with newly diagnosed MM (NDMM) have not been fully defined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 249 NDMM patients diagnosed between January 2008 and October 2019 were included in this retrospective study. Among them, 112 patients received vindesine-based chemotherapy (35 vDD and 77 vAD) and 137 received bortezomib-based chemotherapy (58 VDD and 79 VD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In bortezomib-containing regimens, the complete response rate (48.3 <jats:italic>vs.<\/jats:italic> 30.4%, p = 0.033) and very good partial response or better rate (74.1 <jats:italic>vs<\/jats:italic>. 57.0%, p = 0.038) of VDD were significantly higher than those of VD subgroup. While no superior survival was found between VDD and VD subgroup. In vindesine-containing regimens, no statistical significance was identified between vDD and vAD in terms of response rate and survival. The occurrence rates of all cardiac AEs were similar between VDD and VD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The vDD regimen was similar with vAD in the aspect of response rate, survival, and toxicity in NDMM patients. The addition of PLD to VD brought deeper response without increased toxicity, while no superior survival was found.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.597453","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T15:18:14Z","timestamp":1616685494000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety"],"prefix":"10.3389","volume":"11","author":[{"given":"Yujia","family":"Zhai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueling","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunfeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosheng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangxiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-019-0807-5","article-title":"Incidence and mortality of multiple myeloma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1620947","article-title":"Cost-effectiveness analysis on binary\/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma","volume":"60","author":"Cai","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21662","article-title":"Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial","volume":"106","author":"Rifkin","year":"2006","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2165\/11207510-000000000-00000","article-title":"Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi\u2019s sarcoma","volume":"71","author":"Duggan","year":"2011","journal-title":"Drugs"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","article-title":"New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy","volume":"29","author":"Gabizon","year":"2016","journal-title":"Drug Resist Updat"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1909","article-title":"A Phase I\/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed\/Refractory Multiple Myeloma","volume":"25","author":"Schroeder","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30026","article-title":"Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma","volume":"122","author":"Orlowski","year":"2016","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1773-5","article-title":"Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma","volume":"101","author":"Kusumoto","year":"2015","journal-title":"Int J Hematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00277-010-1052-8","article-title":"A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma","volume":"90","author":"Waterman","year":"2011","journal-title":"Ann Hematol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3816\/CLML.2010.n.008","article-title":"Weekly Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone Is a Safe and Effective Therapy for Elderly Patients With Relapsed\/Refractory Multiple Myeloma","volume":"10","author":"Gozzetti","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13592","article-title":"Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study","volume":"171","author":"Voorhees","year":"2015","journal-title":"Br J Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.5370","article-title":"Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma","volume":"27","author":"Jakubowiak","year":"2009","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S97457","article-title":"Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.003400","article-title":"Evidence That Mitogen-Activated Protein Kinase Phosphatase-1 Induction by Proteasome Inhibitors Plays an Antiapoptotic Role","volume":"66","author":"Small","year":"2004","journal-title":"Mol Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-201053","article-title":"The role of complete response in multiple myeloma","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08884.x","article-title":"A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients","volume":"155","author":"Berenson","year":"2011","journal-title":"Br J Haematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2149","article-title":"Therapy-related peripheral neuropathy in multiple myeloma patients","volume":"33","author":"Morawska","year":"2015","journal-title":"Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.31","article-title":"A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma","volume":"6","author":"Becker","year":"2016","journal-title":"Blood Cancer J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12509","article-title":"An open-label phase I\/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma","volume":"95","author":"Nishihori","year":"2015","journal-title":"Eur J Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-1136-5","article-title":"Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients","volume":"90","author":"Buda","year":"2010","journal-title":"Ann Hematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.51","article-title":"A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed\/refractory multiple myeloma","volume":"26","author":"Berenson","year":"2012","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/bjh.14992","article-title":"Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma","volume":"180","author":"Cohen","year":"2018","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.05.007","article-title":"Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma","volume":"17","author":"Voorhees","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.606943","article-title":"Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease","volume":"53","author":"Landau","year":"2012","journal-title":"Leuk Lymphoma"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.597453\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T15:18:17Z","timestamp":1616685497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.597453\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":29,"alternative-id":["10.3389\/fonc.2021.597453"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.597453","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"article-number":"597453"}}